Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304826 | 0.88 | MEN1 (0.48) | DRD4MEN1KMT2AFAAHSMN1; SMN2 | |
| SCHEMBL4314108 | 0.85 | DRD4 (0.53) | DRD4ADAMTS5MEN1KMT2APOLB | |
| SCHEMBL4964653 | 0.84 | DRD4 (0.42) | DRD4 | |
| SCHEMBL4306625 | 0.84 | CCR3 (0.39) | DRD4MEN1KMT2AMGLL | |
| SCHEMBL4308023 | 0.80 | CCR3 (0.41) | DRD4MEN1KMT2AFAAHSMN1; SMN2 | |
| SCHEMBL4314093 | 0.80 | CCR3 (0.37) | MEN1KMT2A | |
| SCHEMBL4309032 | 0.79 | FAAH (0.41) | DRD4ADAMTS5MEN1KMT2AMGLL | |
| SCHEMBL4311485 | 0.79 | KCNH2 (0.45) | MEN1KMT2APOLBMGLLFAAH | |
| SCHEMBL4306732 | 0.79 | FAAH (0.47) | MEN1KMT2APOLBFAAHSMN1; SMN2 | |
| SCHEMBL13667456 | 0.79 | FAAH (0.47) | MEN1KMT2APOLBFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| CN-101228138-B | Neurotherapeutic azole compounds | SK HOLDINGS CO LTD | 2012-11-21 | — | — | CN | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | DRD4 3219/4885ADAMTS5 897/4885MEN1 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.